drugset / Trial / NCT05294055
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Phase 2
Recruiting
120 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter prospective study to evaluate the efficacy and safety of chemotherapy combined with a single dose of subcutaneous(SC) injection mecapegfilgrastim on day 2 or day 5 after chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma or lymphoma.
Timeline
- Start
- 2022-04-26
- Primary completion
- 2026-03-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mecapegfilgrastim | Protein / enzyme biologic | 12 mg | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 2 g | — |
| Background | Etoposide | Small molecule | 1.5 g | — |
| Background | Etoposide | Small molecule | 1.8 g | — |